Clinical Trial Update: Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating capecitabine as a radiosensitising agent in the neoadjuvant treatment of locally advanced resectable rectal cancer has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Institute of Oncology Ljubljana | Conditions: Resectable Rectal Cancer Clinical Stage II and III | Phase 2 | Status: COMPLETED